DRUG PRODUCT FORMULATIONS
Current Formulations
Matrix Biomed, Inc. has developed three (3) formulations with the active ingredient 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl : MTS-01, MBM-01, and MBM-02. 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl has been shown to be a potent inhibitor of master genes responsible cancer growth and development, hypoxia inducible factor -1 (HIF-1) and hypoxia inducible factor-2 (HIF-2)
Solid tumors contain hypoxic regions (low oxygen) due to their high rates of cell proliferation and formation of aberrant blood vessels. Intratumoral hypoxia is associated with increased risk of invasion, metastasis, and patient mortality. Cancer cells respond to hypoxia by stabilizing hypoxia-inducible factor 1 (HIF-1) and hypoxia inducible factor 2 (HIF-2). HIF-1 and HIF-2 activate a transcription of genes encoding proteins that mediate major adaptive responses to hypoxia that are critical for cancer cell survival. Without activation of HIF-1 and HIF-2, cancer cells would not survive. 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl inhibits HIF-1 and HIF-2 starving cancer cells without adversely impacting healthy cells.
MTS-01
The MTS-01 drug product is a topical gel containing 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl. The composition of MTS-01 is used for indications requiring topical applications of the lead compound. Such indications include the prevention of radiation dermatitis, psoriasis, and other inflammatory skin conditions. MTS-01 blocks inflammatory pathways.
MBM-01
The drug product MBM-01 is a 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl oral solution.
The composition of MBM-01 is administered to patients who have difficulty swallowing capsule formulations. MBM-01 is a potent inhibitor of the master genes responsible for cancer growth and progression, HIF-1 and HIF-2. Additionally, MBM-01 inhibits inflammatory pathways triggered by chemotherapy and radiation.
MBM-01 is currently being tested in phase II clinical trials to prevent the side effects of chemotherapy and radiation.
MBM-02
The drug product MBM-02 is a 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl capsule.
MBM-02 is a potent inhibitor of the master genes responsible for cancer growth and progression, HIF-1 and HIF-2. Additionally, MBM-02 inhibits inflammatory pathways triggered by chemotherapy and radiation.
MBM-02 is currently being tested in phase II clinical trials to treat brain cancer and prostate cancer.
